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INTRODUCTION
Intestinal/colonic amebiasis or amebic colitis is an
infection caused by Entamoeba histolytica, protozoan
parasite which has capability to invade intestinal
 mucosa and spread to other organ specially the liver.1
Entamoeba histolytica is currently found in all over
the world, and high prevalence is in high risk region in
tropical and subtropical countries.2 The prevalence of
amebiasis is greatly varied; estimating that 10%
population are infected and has the highest prevalence
in tropical countries accounting for 50-80%.3
E histolytica infection can also be found in  developed
countries and frequent infected groups are those who
are immigrants, travelers, refugees, prisoners, patients
at mental hospital and male homosexual.2,4 According
to recent data of WHO, amebiasis is responsible for
70,000 deaths worldwide every year. This has made
amebiasis to be the fourth leading cause of death due
to protozoan infection after malaria, Chagas disease
and leishmaniasis and it is also third cause of morbidity
after malaria and trichomoniasis.1
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ABSTRACT
Intestinal amebiasis is an infection due to Entamoeba Histolytica and has the highest prevalence in
tropical countries, including Indonesia. Amebiasis is responsible for approximately 70,000 deaths
annually every year. High prevalence is found especially in endemic area which had poor hygiene and
sanitation or crowded population. Human is the main reservoir, while the disease can be transmited by
mechanical vector such as cokckroach and flies.
Making diagnosis of intestinal amebiasis sometimes can be a problem. Clinical presentation and
disease severity may be varied. Complication due to late management of the disease can be fatal. Lifestyle
education, early diagnosis and proper management of amebiasis are very important measures to promote
by health workers.
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According to UNESCO, global burden of
amebiasis currently is more than 50 million people
infected symptomatically and up to 100,000 people die
every year.5 Cohort study in developing countries
underlined the critical health issue of amebiasis. For
example in Dhaka, Bangladesh; diarrhea is main cause
of death in children. A 2-years prospective study on
preschool age children demonstrated that 55%
subjects had E histolytica infection. Annual incidence
of amebic colitis is 2.2% and similar to Shigella
disentriae in this cohort study.5
Human is the main reservoir and host of
E histolytica infection. Infection may be transmitted
by feces contamination on food and drinking water by
mechanical vectors such as flies, cockroach, or by
person-to person contacts and anal-oral sexual
contact. Poor hygiene, crowded population, inadequate
and contaminated water supply, worse individual
sanitation have all give access to transmission of
amebiasis.1,3 This disease is more severe in very young
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patients, elderly, neonatus, pregnant women, post
partum, malignancy, malnutrition and patients on
steroid treatment.6,7 The prevalence of colonic disease
is not very much different between male and female.
However, liver amebic abscess and other extra
intestinal disease are 3-10 times higher in male.7
In Indonesia as developing and tropical country,
intestinal amebiasis is an important matter and can be
a critical health problem for its population. There are
still some technical and non-technical problems in
making diagnosis and management of amebiasis. This
paper will review further on pathogenesis, clinical
presentation, and current management of amebiasis.
PATHOGENESIS OF INTESTINAL/COLONIC
AMEBIASIS
Intestinal/colonic amebiasis is infection of intestine/
colon caused by protozoan Entamoeba histolytica.
E histolytica exists in two forms; cyst and motile
trophozoites.  The infection starts when contaminated
food or water that containing cyst is swallowed by
human. Inside intestinal lumen, cyst wall is broken down
and thus releasing trophozoites which will become
mature in colonic lumen (figure 1). Trophozoites is a
causative agent of invasive disease but has no role in
transmission of disease because of rapid degeneration
of trophozoitesoutside the human body and destruction
by gastric acid.7 Trophozoites use galactose and lectin
specific N-acetyl-D-galactosamin (Gal/GalNAc) to
adhere to colonic mucin and colonize in colon.1,2,5,6,7,8
Amebic colitis occurs when trophozites penetrate
intestinal mucosal layer which is actually the barrier to
invasion; by inhibit adherence of ameba to epithelial
layer and inhibit the trophozoit motility. Invasion is
mediated by the destruction of epithelial, neutrophils
and lymphocyte cells by trophozoite if lectin of
the parasite binds N-acetyl-D-Galactosamin at O-linked
of surface cell of the host. The secretion through
amebapore; a pore forming protein sized 5 kD has
contribution to the destruction of the cells.7,8,9,10
Based on isoenzyme pattern, E histolytica is
classified into 2 groups: pathogenic and non-pathogenic
zymodeme.3 Although Brumpt postulated in 1925 that
there were 2 species of Entamoeba that could not be
differentiated morphologically. One was known to cause
the disease and the other one could not. Later in 1990,
genetic molecular examination had confirmed from the
two isoenzymes that they were actually two
genetically different species but had the same
morphology. One that cause invasive amebiasis is called
E histolytica and the other one E dispar which is a
nonpathogenic protozoan paracyte.7,8
Invasive disease is characterized by the release of
toxic substance that cause inflammation and destruct
mucosal layer.1,11,12 If the process continue,
flask-shaped ulceration will occur extending to
sub mucosa or muscularis layer. In some cases,
amebic invasion extends more to portal circulation in
the liver, thus causing amebic liver abscess. The edge
of ulcer is slightly condensed with inflammation.
Mucosa between ulcers appears normal. Ulceration
may be found in all parts of colon but most frequent is
in caecum, followed by ascending colon, sigmoid,
appendices and terminal ileum. Due to amebic
invasion to intestine wall, humoral immune reaction and
cell-mediated amebisidal will occur such as
macrophage lymphokine-activated and CD8 cytotoxic
lymphocyte.1,13 Several studies demonstrated that
cystein protein of E histolytica had important role in
amebic invasion to intestinal tissue and stimulate
inflammation by activating interleukin-1 (IL-1) of
the host.5,7 After the adherence of trophozoites to
colonic mucin, amebic cystein proteinase will degrade
mucin and facilitate penetration. Contact with
epithelial cells will kill host cell by mechanism of
apoptosis and necrosis. It also will activate epithelial
inflammation that characterized by activation of
NF-κB, pre-IL-β, IL-1α, IL-8, IL-6, COX-2, GRO-a
and GM-CSF secretion and leukocyte
involvement.5,13,14 Amebic cytotoxicity and tissue
destruction induced by neutrophils allow deep
penetration of ameba5,6,7 (see figure 2). Invasion that
reach muscularis layer of colon can cause granulation
mass that is known as ameboma frequently found in
caecum and ascending colon. E histolytica can also
induce severe inflammation and make it difficult to
differentiate with inflammatory bowel disease (IBD).
Severe amebic invasion is likely to be found in
immunosupressed patients such as those who are on
steroid treatment.1,7
During chronic infection, E histolytica avoid host
response immune by various mechanisms. Lectin
specific Gal/GalNAc has similarity in chain and
antigenic cross reaction with CD 59, a human
leukocyte antigen which prevent formation of comp
lement C5b-C9 membrane. Glycosylphosphatidily-
nocytol bindslypophosphoglycan/proteophosphoglycan
(LPG) which covers trophozoites and functioning as
protection to complement. Amebic systein proteinase
also degrades serum IgA and IgG that might protect
ameba from opsonisation. Ameba might also inhibit
macrophage breakdown and suppress antigenic
presentation by major histocompability complex (MHC)
molecules class II.2,5
Model for the step-wise invasion of the colonic
mucosa by the Entamoeba histolytica in figure 1.
Infection begins with excystation and adherence of
trophozoites to colonic mucins. Amebic proteinases
degrade mucins and facilitate penetration. Contact with
epithelial cells lead to apoptotic and necrotic host cell
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killing and activation of an epithelial cell inflammatory
program marked by: (i) activation of NF-kB;
(ii)secretion of per-IL-1β, IL-1-α, IL-8, IL-6, COX-2.
GRO-α and GM-CSF; and (iii) recruitment of
leukocytes. Amebic cytotoxicity and neutrophil-induced
tissue damage enable deep penetration by amebae and
lateral spread. During chronic infection, amebae evade
the host immune response, and inflammation is often
minimal given thetissue destruction. However T cells
and macrophages recruited to the sight of chronic
infection might contribute to disease by autoimmune
mechanisms.Abbreviations: COX-2, cyclooxygenase 2;
Gal/GalNAc,D-galactose/N-acetyl-D-galactosamine;
GRO, growth-related oncogene; GM-CSF,
granulocyte-macrophage colony-stimulating factor; IL,
interleukin; NF-κB, nuclear factor-κB.
CLINICAL SYMPTOMS
The clinical manifestations of intestinal amebiasis
range from mild diarrhea to classic dysentri
intestinal disease.1,2,3,5,6 Patients with amebic colitis
usually complaint of abdominal tenderness for few
weeks, weight loss, diarrhea and bloody stool.3,15,16
Onset of disease is not very clear. The various clinical
presentations have made difficulties in making
diagnosis because sometimes patients have no fever
or bloody stool.2
 Some clinical conditions of patients with
amebiasis:
1. Carrier (cyst passer)
Ameba does not invade to intestine wall. Usually
patients are asymptomatic or having mild complaints
such as bloating, flatulence, obstipation, and
sometimes diarrhea. Ninety percent of patients are
self-limiting disease in a year, and the rest 10%
develop amebic colitis.3
2. Mild amebic dysentri
Patients’ complaint of abdominal fullness, mild
abdominal tenderness, mild fever, and mild
diarrhea with stinky stool mixed with blood and
mucus. The general condition of patients is good
3. Moderate amebic dysentri
Patients may complaint of abdominal rigidity,
fever, hepatomegaly with pain
4. Severe amebic dysentri
Clinical presentations such as diarrhea with bloody
stool, high fever, nausea and anemia
5. Chronic amebic dysentri
The symptoms are similar to mild amebic dysentri
with asymptomatic period interval. It may last for
months or even years. Sometimes with
neurasthenia, diarrhea occurs in association of
fatigue, fever or maldigestive food.
Other manifestations of more severe amebiasis but
rarely occur are acute necroticans, toxic megacolon,
ameboma, and perianal ulceration which can develop
fistulae. Acute necrotican colitis is rare, accounts less
than 0.5% of cases with mortality rate more than 40%.
In general, patients are in severe condition, have fever,
mucous bloody diarrhea, abdominal tenderness and sign
of peritoneal irritation. Surgical intervention is indicated
if there were intestinal perforation or unresponsive to
anti ameba therapy. Toxic megacolon in amebic colitis
is rare and usually related to administration of
corticosteroid in intestinal amebiasist.7 Early detection
of complication and surgical intervention is important
for such patients who are frequently unresponsive to
anti amebic therapy. Rarely, a localized amebic colonic
infection results in a segmental mass of granulation
tissue forming an ameboma. Amebomas are found in
decreasing order of frequency in the caecum,
ascending colon, rectosigmoid, transverse colon, and
descending colon. The ameboma can be mistaken for
a carcinoma.2,7 It can be detected on physical
examination as a tender palpable mass.7
DIAGNOSIS
In patients suspected of intestinal amebiasis, first
laboratory examination is stool analysis to detect
erythrocyte in stool. If result of stool examination were
positive, then other supporting examination can be done
(as seen in diagnosis algorithm). Intestinal amebiasis is
diagnosed if cyst or motile trophozoites are identified
in stool analysis. The lack of this method is low
sensitivity and high false positive for infections of
E dispar or E moshkowskii. Ideally, the diagnosis
should be based on serologic test of specific antigen or
Figure 1. Pathogenesis of intestinal amebiasis5
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DNA of E histolytica and the presence of anti ameba
antibody in the sera (see table 1). At least 3 specimens
of feces which are taken at 3 different times are needed
for the examination because organism is intermittently
secreted and not well-distributed in the feces.
Serologic examination to detect the presence of
ameba is positive in 85-95% of patients with invasive
amebic infection or liver abscess. Because antiamebic
antibodies may persist for months and years after the
eradication of infection, a positive serology requires
more rigid clinical and diagnostic correlation in endemic
areas. Indirect hemagglutination (IHA) is the most
sensitive assay, and it yields positive results in 90% to
100% of subjects with liver abscess, 75% to 90% of
subjects with symptomatic intestinal infection, and 5%
to 50% of subjects with asymptomatic infection.7
Antibody may be negative early in the course of an
acute infection. It is therefore important to repeat the
serology 5 to 7 days later if the initial study results are
negative.
Endoscopy is useful in making diagnosis of colitis
ameba and should be performed without previous bowel
preparation in order to increase the chance of
detecting amebas in the colonic mucus. Discrete
shallow-based ulcers covered with yellow or white
exudates with intervening areas of edematous mucosa
are often found in invasive amebic colitis. Mucosa
around the ulcers is usually normal. Trophozoite form
can be found at the base of ulcer by scrapping or
aspiration to obtain the specimen. The diagnostic yield
from endoscopic biopsy samples or scrapings is high.7
Trophozoites are usually easily identified in these
specimens by routine light microscopy, but
immunohistochemical staining for E histolytica may
further increase the yield.6
Radiologic examination is not very useful because
the appearance may be varied and non specific.
Ameboma may appear as filling defect. The scanning
procedure should be performed in all cases of
suspected liver abscess. Abdominal CT usually
demonstrates localized, low density lesion with
definite borderline.
Antigen detection test to diagnose E histolytica
infection shows the three methods have almost the same
yield. The important things in antigen detection test and
PCR based test are serum antibody to ameba
detection that is found in 70-90% patients with
symptomatic E histolytica infection.6
DIFFERENTIAL DIAGNOSIS
The similarities in symptoms between amebiasis and
inflammatory bowel disease have made amebiasis
should be excluded by examination of stools or amebic
serology in all patients before a diagnosis of
inflammatory bowel disease is made and especially
before  corticosteroid therapy is begun.7
The differential diagnosis of invasive intestinal
amebiasis includes infection with Shigella,
Campylobacter, and other invasive bacteria, as well
as pseudo membranous colitis secondary to
Clostridium difficile, CMV colitis.3,7
The ameboma can be mistaken for a carcinoma on
barium enema. Amebic strictures are most commonly
observed in the anus, rectum, or sigmoid colon and must
be differentiated from those due to lymphogranuloma
venereum (chlamydia) or malignancy.7
COMPLICATIONS
1. Intestinal, colonic bleeding, perforation, peritonitis,
ameboma, intussusceptions, and stricture.
2. Extraintestinal. With the most common
manifestation is liver abscess. Usually, patients are
complaint of fever, upper quadrant abdominal pain,
leukocytosis, and abnormal liver function test and
elevated phosphatase alkaline level.7
Most of complications are associated with abscess
rupture. Brain amebic abscess is rarely occurred.
But has high mortality rate. There had been many
medical reports on the involvement of
genitourinary tract including perinephric abscess,
splenic abscess, rectovaginal fistula, cervices
ulcer, uterine involvement and vaginal lesion. There
Table 1. Sensitivity of test for the diagnosis of amebiasis 
Test Colitis (%) 
Liver 
abscess
(%) 
Microscopy 
Stool 
Abscess fluid 
 
25 – 60 
NA 
 
10 – 40
≤ 20 
Antigen detection 
Stool 
Serum 
 
 
Abscess fluid 
 
90 
65 
(early) 
 
- 40 
- 100 
(before
treatmen
- 40 
Indirect hemagglutination (antibody) 
Serum obtained during acute illness 
Serum obtained during convalescence 
 
70 
> 90 
 
70 – 80
> 90 
* NA denotes not applicable 
Stool examination for occult bleeding
Positive
Stool examination of at least 3 specimens
Identifity trophozoite, tricome staining for cyst, serologic test of anti ameba
Positive
Negative
further examination is unnecessary
Negative
Colonoscopy with biopsy
(especially in the ulcer  edge)
Treatment of amebicid
Positive
 Figure 2. Amebic colitis diagnosis algorithm
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for 5 days
3) Trinidazole, 50 mg/kgBW or 2 g/day for
2-3 days
4) Ornidazole, 50-60 mg/kgBW or 2 g/day for
3 days
b. Mild to moderate intestinal amebicid
Tetracycline 500 mg tid for 5 days or
metronidazole 500 mg tid for 5-10 days
c. Severe intestinal amebiasis
Metronidazol 750 mg tid for 5-10 days.17,19,20
Tetracycline 500 mg tid for 5 days and emetine
1 mg/kgBW/day IM (maximal 60 mg) for 10 days
d. Extraintestinal amebiasis, using 3 regimens of drugs
- Metronidazole 750 mg tid for 5-10 days
- Chloroquine phosphate 1 g/day for 2 days
continued by 500 mg/day for 4 weeks
- Emetine 1 mg/kgBW/day IM (maximal 60 mg)
for 10 days
Metronidazole is (1b-hydroxy-ethyl)-2 methyl-5-
netroimidazole which has yellowish crystal form and
mildly dissolve in water or alcohol.17 The half time ranges
from 9 to 10 hours. Beside thricomoniacid effect,
metrononidazole is also effective for treatment of
Giardia lambdia. To date, resistance of E histolytica to
metronidazole has not become a problem yet.7 Other
drugs that have similar structure and activity with
metronidazole are tinidazole, nimorazole, and ornidazole.
These three drugs have longer half time than
metronidazole, so that they can be given once daily.7,17
Common side effects of metronidazole include
nausea, headache, metallic taste, and abdominal
discomfort; ataxia, confusion, insomnia, and
paresthesias may occasionally occur. The most
serious side effects are central nervous system effects
(psychosis, seizures), which mandate cessation of
the drug.
Emetine is an effective drug to kill throphozoites in
tissue or intestinal wall but ineffective for ameba in
the intestinal lumen.3,14 It is relatively toxic, may cause
diarrhea, abdominal cramps, tachycardia, hypotension,
precordial pain and ECG abnormalities such as T wave
inversion and prolonged QT interval. Other
manifestation of arrhythmia such as wide QRS
complex is more rarely. Patients who are given
emetine should be bed rest and have ECG monitor.
Avoid the use of emetine if there is kidney, heart, or
muscular disorder, or in pregnancy or children unless
other drugs are considered failed.3
The need for vaccine
Ideally, amebiasis is prevented by eradicating
feces contamination of food and water. However, to
provide uncontaminated food and water in developing
countries need huge investments and social changes.
Vaccine is urgently needed. Human will naturally get
the partial immunity against intestinal infection. In this
had also been some reports on skin, nail, and
pleuropulmonal amebiasis.
MANAGEMENT
Medical treatment
Patients with E histolytica infection should receive
antiamebic therapy, but there is no evidence that
patients with E dispar infection require treatment.7 Prior
to the general availability of assays that distinguish
between infection with E histolytica and E dispar,
treatment decisions must be based primarily on
the clinical presentation. The goals of treatment are to
treat the invasive disease and eradicate intestinal
carriage of the organism. Based on the site of actions,
amebicid is divided into 3 categories:17
1. Tissue amebicid
Drugs that mainly act on intestinal wall, liver and
other extraintestinal tissues include dehydroemetine,
emetin, and choloroquine.
2. Luminal amebicid
It works in lumen of intestine and is called contact
amebicid. Drugs that included in this category are
diodohydroxyquine,iodochlorhydroxyquin,chiniophone,
glycobiarsol, carbarsone, emetine bismuth iodide,
clefamide, diloxasanid furoat, and some other
antibiotics such as tetracycline and paromomycine.
3. Amebicid of intestinal lumen and tissue
(e.g. metronidazole)
According to severity of clinical symptoms,
recommended treatment is as follow:
a. Asymptomatic or carrier 3,18
Amebiasis without clinical symptoms should be
treated because ameba that lives commensally
in colon can change to be pathogenic at any
time. Besides, carrier could be the main source
of infection. Recommended drugs given as
luminal amebicid are:
1) Iodoquinol (diiodohidroxyquin) 650 mg tid
for 20 days
2) Diloksanil furoat, 500 mg tid for 10 days.
Now this is the treatment of choice because
it is highly effective (80%-85%), while
the minimal side effects are only nausea
and abdominal bloating
3) Carbarsone,  500 mg tid for 7 days
4) Clefamide, 500 mg tid for 10-13 days
5) Paromomycine, 500 mg tid for 5 days
Because the risk of amebic invasion to intestinal
mucosa is high although it does not disturb peristaltic
movement, addition of tissue amebicid is recommended.
The choices of drugs are as follows;
1) chloroquine diphosphate, 500 mg bid for
1-2 days, continue with dose of 250 mg bid for
7-12 days
2) Metronidazole, 35-50 mg/kgBW or 500 mg tid
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case, according to several studies, there are some
recombinant antigen including lectin specific Gal/
GAlNAc can be used.5,21 However, further studies are
needed to develop this vaccine.
CONCLUSION
The high prevalence of colonic amebiasis due to
protozoa; Entamoeba histolytica is found in tropical
countries. Ameba infection begins by swallowing of
infected cysts containing amebas in food or water which
are contaminated by feces. Colitis occurs as trophozoit
penetrates intestinal mucosal layer mediated by
neutrophils and infection binding to N-acetyl-D-
galactosamin of O-linked oligosaccharide on cell
surface.
During  chronic infection of E histolytica is against
immune response by various mechanisms including
lectin specific of Gal/Gal/Nac which has similarity of
chains and antigenic cross reactivity to CD 59 with
clinical symptoms of intestinal amebiasis are varied
from asymptomatic, dysenteric diarrhea and intestinal
involvements
Diagnosis is made from anamnesis, physical
examination, supporting examinations including stool
analysis, serologic examination, endoscopic and
radiologic examinations. Management of intestinal
amebiasis includes medical treatment of metronidazole,
chloroquine, emetin, and tetracycline. Lifestyle
education and good sanitation are also important to be
promoted. In the future vaccination will be highly
needed to decrease prevalence of intestinal
amebiasis.
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Table 1. Drug therapy for the treatment of amebiasis20 
Drug Adult dosage Pediatric dosage Side effect 
Amebic liver abscess 
   
 give  
Metronidazole 750 mg orally 3 times 
a day for 7-10 days 
35-10 mg/kg of body 
weight/day in 3 divided 
doses for 7-10 days 
Primarily gastrointestinal: anore
nausea, vomiting, diarrhea, abd
discomfort, or unpleasant metal
taste; disulfuram-like intolerance
reaction with alcohol; rarely, 
neurotoxicity, including seizures
peripheral neuropathy, dizzines
confusion, irritability 
 
or 
 
Tinidazole †    800 mg orally 3 times 
a day for 5 days 
60 mg/kg/day  
(max 2 g) for 5 days 
Primarily gastrointestinal and 
disulfuram-like intolerance reac
for metronidazole 
 
followed by a luminal agent  
Paromomycin 25-35 mg/kg/day in 3 
divided doses for 7 
days 
25-35 mg/kg/day in 3 
divided doses for 7 day 
Primarily gastrointestinal: diarrh
gastrointestinal upset 
 
or second-line agent  
Dilocanide furoate ‡ 500 mg orally 3 times 
a day for 10 days 
20 mg/kg/day in 3 
divided doses for 10 
days 
Primarily gastrointestinal: flatule
nausea, vomiting, pruritus, urtic
Amebic colitis 
   
 give  
Metronidazole 750 mg orally 3 times 
a day for 7-10 days 
35-50 mg/kg/day in 3 
divided doses for 7-10 
days 
As for amebic liver abscess 
 
followed by a luminal agent (as for amebic liver 
abscess) 
 
Asymptomatic 
intestinal colonization 
   
 
give  
Paromomycin 25-35 mg/kg/day in 3 
divided doses for 7 
days 
25-35 mg/kg/day in 3 
divided doses for 7 day 
Primarily gastrointestinal: diarrh
gastrointestinal upset 
 
or second-line agent  
Dilocanide furoate ‡ 500 mg orally 3 times 
a day for 10 days 
20 mg/kg/day in 3 
divided doses for 10 
days 
Primarily gastrointestinal: flatule
nausea, vomiting, pruritus, urtic
† This drug is not yet available in the United States 
‡ This drug is not available in the United States 
